StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock.
Several other analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st.
View Our Latest Stock Analysis on Can-Fite BioPharma
Can-Fite BioPharma Stock Down 2.5 %
Institutional Trading of Can-Fite BioPharma
An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC raised its stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is currently owned by hedge funds and other institutional investors.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
See Also
- Five stocks we like better than Can-Fite BioPharma
- Airline Stocks – Top Airline Stocks to Buy Now
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- P/E Ratio Calculation: How to Assess Stocks
- Oilfield Leader SLB: An AI Name You Need to Know
- Best Stocks Under $5.00
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.